Contineum Therapeutics/$CTNM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Contineum Therapeutics
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
Ticker
$CTNM
Sector
Primary listing
Employees
41
Headquarters
Website
CTNM Metrics
BasicAdvanced
$333M
-
-$2.20
-
-
Price and volume
Market cap
$333M
52-week high
$18.47
52-week low
$3.35
Average daily volume
194K
Financial strength
Current ratio
24.513
Quick ratio
24.325
Long term debt to equity
2.5
Total debt to equity
3.355
Profitability
EBITDA (TTM)
-65.738
Management effectiveness
Return on assets (TTM)
-20.42%
Return on equity (TTM)
-29.24%
Valuation
Price to book
1.8
Price to tangible book (TTM)
1.8
Price to free cash flow (TTM)
-6.568
Free cash flow yield (TTM)
-15.23%
Free cash flow per share (TTM)
-1.809
Growth
Earnings per share change (TTM)
-32.85%
What the Analysts think about CTNM
Analyst ratings (Buy, Hold, Sell) for Contineum Therapeutics stock.
Bulls say / Bears say
As of June 30, 2025, Contineum had $20.8 million in cash and $154.7 million in marketable securities—totaling $175.5 million—to fund operations through mid-2027 and support upcoming clinical milestones (Form 10-Q, June 30, 2025).
Contineum finished enrollment in its PIPE-307 Phase 2 VISTA trial ahead of schedule. The last patient is expected to complete in Q3 2025, with topline data expected in Q4 2025, positioning the company for a key clinical milestone (Business Wire).
The company plans to file an IND for its third pipeline asset, CTX-343, in the second half of 2025—broadening its NI&I pipeline beyond its main programs and adding potential long-term value (SEC Filing).
Contineum reported a net loss of $16.0 million in Q2 2025, showing continued cash burn with no offsetting revenue (Form 10-Q, June 30, 2025).
Research and development expenses rose 78.5% year-over-year to $14.1 million in Q2 2025, accelerating cash outflow and increasing financing risk (Nasdaq).
Management decided to delay the planned PIPE-791 PrMS and CTX-343 trials to focus resources on IPF, highlighting execution risk and the potential for broader pipeline delays (BioSpace).
Data summarised monthly by Lightyear AI. Last updated on 29 Sept 2025.
CTNM Financial Performance
Revenues and expenses
CTNM Earnings Performance
Company profitability
CTNM News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Contineum Therapeutics stock?
Contineum Therapeutics (CTNM) has a market cap of $333M as of October 12, 2025.
What is the P/E ratio for Contineum Therapeutics stock?
The price to earnings (P/E) ratio for Contineum Therapeutics (CTNM) stock is 0 as of October 12, 2025.
Does Contineum Therapeutics stock pay dividends?
No, Contineum Therapeutics (CTNM) stock does not pay dividends to its shareholders as of October 12, 2025.
When is the next Contineum Therapeutics dividend payment date?
Contineum Therapeutics (CTNM) stock does not pay dividends to its shareholders.
What is the beta indicator for Contineum Therapeutics?
Contineum Therapeutics (CTNM) does not currently have a Beta indicator.